Background: New methods are needed to detect precancerous lesions in lung tissue. We conducted a study to determine the utility of LIFE™ (laserinduced fluorescence emission) autofluorescence bronchoscopy for the detection of squamous metaplasia and dysplasia in current and former smokers. Methods: In this prospective, single-center study, 53 participants underwent standard white-light bronchoscopy and 39 underwent both white-light and LIFE bronchoscopy. Bronchial biopsy specimens were obtained from all participants at six predetermined sites using white-light bronchoscopy and from all other sites that appeared to be abnormal in participants who underwent LIFE bronchoscopy. Relationships between LIFE imaging and histologic findings were examined for 245 biopsy specimens obtained from those participants who had undergone LIFE bronchoscopy. Results: LIFE imaging revealed abnormalities designated as either class II or class III in 89 (36.3%) and 16 (6.5%) of the 245 sites examined, respectively, and histopathologic examination showed dysplasia and metaplasia in eight Chemoprevention of lung cancer (i.e., inhibition of lung carcinogenesis) will require a better understanding of the biology of premalignant bronchial lesions and the development of effective chemopreventive agents. Following the sequential progression model of lung carcinogenesis proposed by Saccomanno et al. (1), many investigators have used sputum atypia as a study end point to evaluate the efficacy of retinoids (i.e., vitamin A compounds) and other chemopreventive agents (2-4). However, because of the high variability of cytologic findings in sequential sputum samples, no definitive conclusions could be made regarding the efficacy of the chemopreventive agents used in those trials. As an alternative, we (5) and others (6) have used histologic findings of squamous metaplasia and dysplasia in bronchial biopsy samples as a study end point. In our first randomized clinical trial to test a chemopreventive agent in patients with precancerous lesions of the bronchi (5), all eligible smokers (ജ15 pack-years [pack/day × years smoked]) with detectable squamous metaplasia (based on a metaplasia index that quantitates metaplasia in serial sections [% positive sections]) or dysplasia were randomly assigned to receive 13-cis-retinoic acid (13cRA) or placebo, and bronchoscopy with biopsy sampling was repeated after 6 months of treatment. That trial revealed that even the histologic findings of squamous metaplasia were highly variable over time, and there was a statistically significant reversal of squamous metaplasia in association with smoking cessation (5). Because precancerous changes in bronchial epithelium were not visible with a standard white-light bronchoscope, we decided to evaluate the usefulness of potentially better detection tools such as the laser-assisted autofluorescence bronchoscope.
Chemoprevention of lung cancer (i.e., inhibition of lung carcinogenesis) will require a better understanding of the biology of premalignant bronchial lesions and the development of effective chemopreventive agents. Following the sequential progression model of lung carcinogenesis proposed by Saccomanno et al. (1) , many investigators have used sputum atypia as a study end point to evaluate the efficacy of retinoids (i.e., vitamin A compounds) and other chemopreventive agents (2) (3) (4) . However, because of the high variability of cytologic findings in sequential sputum samples, no definitive conclusions could be made regarding the efficacy of the chemopreventive agents used in those trials. As an alternative, we (5) and others (6) have used histologic findings of squamous metaplasia and dysplasia in bronchial biopsy samples as a study end point. In our first randomized clinical trial to test a chemopreventive agent in patients with precancerous lesions of the bronchi (5), all eligible smokers (ജ15 pack-years [pack/day × years smoked]) with detectable squamous metaplasia (based on a metaplasia index that quantitates metaplasia in serial sections [% positive sections]) or dysplasia were randomly assigned to receive 13-cis-retinoic acid (13cRA) or placebo, and bronchoscopy with biopsy sampling was repeated after 6 months of treatment. That trial revealed that even the histologic findings of squamous metaplasia were highly variable over time, and there was a statistically significant reversal of squamous metaplasia in association with smoking cessation (5) . Because precancerous changes in bronchial epithelium were not visible with a standard white-light bronchoscope, we decided to evaluate the usefulness of potentially better detection tools such as the laser-assisted autofluorescence bronchoscope.
The laser-induced fluorescence emission (LIFE™) system (Xillix Technologies, Vancouver, Canada) is an autofluorescence bronchoscope that was developed to detect early bronchogenic cancers on the basis of their autofluorescent spectra. The autofluorescent spectra of dysplasia and carcinoma in situ were reported to be substantially different from those of normal bronchial tissues when excited by violet (405 nm) or blue (442 nm) light (7) . This difference has been reported to be useful in the detection of bronchial premalignancies that are undetectable when using white-light bronchoscopy. In individuals with known or suspected lung carcinoma, the LIFE system was found to be 50% more sensitive than standard white-light techniques in the detection of moderate/severe dysplasia and carcinoma in situ (8) . The LIFE system was recently approved by the U.S. Food and Drug Administration as an adjunct to white-light bronchoscopy for the detection of moderate/severe dysplasia and car-cinoma in patients with known or suspected lung carcinoma. In this study, we examined the utility of autofluorescence bronchoscopy using the LIFE system in the detection of squamous metaplasia and dysplasia in current and former smokers.
Methods

Study Location and Case Selection
Participants were enrolled into two ongoing, randomized, placebo-controlled clinical trials conducted at the M. D. Anderson Cancer Center, Houston, TX. These trials are being conducted to examine the activity of 4-hydroxyphenylretinamide (4-HPR) or 13cRA plus ␣-tocopherol in the reversal of squamous metaplasia and dysplasia. Participants were recruited through the outpatient clinics at the M. D. Anderson Cancer Center and through referral networks in the Houston metropolitan area. Eligibility criteria for these trials include a smoking history of at least 20 pack-years (considering cigarettes only) and, for the 13cRA plus ␣-tocopherol trial, participants must have stopped smoking for at least 1 year. Participants may have had a tobacco-related cancer (lung, head and neck, or bladder), but they were required to be free of cancer at the time of enrollment. No women of childbearing potential or sexually active men were eligible except those using strict contraception. Participants must have adequate cardiac, pulmonary, and bone marrow function to undergo bronchoscopy with biopsies, and they must have signed an informed consent approved by the institutional review board. From February 1996 through September 1996, 39 participants were evaluated with both white-light and LIFE bronchoscopy (LIFE group). Also included in the analysis are the data from 53 participants who were enrolled in the study before the LIFE bronchoscopy became available in our institution. These participants were evaluated with white-light bronchoscopy alone and served as a control group.
Bronchoscopy and Bronchoscopic Biopsies
Bronchoscopic examination was performed by one of two investigators (RC Morice and GL Walsh) who were trained in the use of the LIFE system by investigators from Xillix Technologies. Bronchoscopic findings were recorded by polaroid photography and by videotape. Autofluorescence findings were graded by the characteristics of autofluorescent emission spectra using criteria established by investigators at Xillix Technologies (Fig. 1) . Previously, class I represented normal bronchial epithelial histology; class II represented angiomas, asthma, acute bronchitis, biopsy sites, granuloma, inflammation, trauma, scar tissue, anatomical abnormalities, and mild dysplasia; and class III represented changes suggestive of moderate or severe dysplasia, carcinoma in situ, and invasive cancer (8) .
Bronchoscopic biopsies were performed at six predetermined sites in each participant, including the main carina; right upper, middle, and lower lobes; left upper and lower lobes; and at all additional sites in the bronchial tree found to appear abnormal by LIFE bronchoscopy. For a specific lobe of the lung, biopsies were performed at sites found to be abnormal by LIFE imaging in lieu of a biopsy at the predetermined biopsy site. All biopsy results included in this study were obtained from participants at baseline, prior to their random assignment to a treatment arm, to avoid any alterations in LIFE findings that could be attributed to retinoid treatment. Ten histologic sections were examined per biopsy site for histologic abnormalities following formalin fixation and staining in hematoxylin-eosin. Histologic examination of the biopsy samples in this study was performed by a single pathologist (J. Y. Ro). In addition, two randomly selected sections from each of 251 biopsy specimens were independently reviewed by another pathologist (W. A. Franklin). Metaplasia Indices (tissue sections containing metaplasia/total sections analyzed) were calculated by the method of Mathé et al. (6) , as previously reported (5) , using the data obtained from the six predetermined biopsy sites.
Statistical Analysis
Both patient-specific and site-specific parameters were used as analysis units in this study. Descriptive statistics were used to summarize patient characteristics, pathologic evaluations of bronchial biopsies, and LIFE-imaging analysis of bronchial biopsy specimens. The Cochran-Mantel-Haenszel statistical test was used to analyze the association between pathologic evaluation of bronchial biopsy sites and LIFE-imaging analysis of bronchial biopsy specimens. The Fisher's exact test and Pearson's chisquared test were applied to a contingency table analysis to reveal the association of LIFE imaging with cancer history and smoking status. All P values resulted from use of two-sided statistical tests.
Results
Participant Characteristics
The characteristics of the participants are shown in Table 1 . The mean age and percentage of participants with a prior cancer history were not significantly different in the two groups, but a higher percentage (85% versus 44%; P<.001 by Fisher's exact test) of participants were current smokers in the control group. The most common prior cancers in these participants were non-small-cell lung cancer (10 in the control group and 11 in the LIFE group) and head and neck cancers (six in the control group and three in the LIFE group). One control group participant had melanoma, and two LIFE group participants (one each) had transitional cell carcinoma of the bladder and breast carcinoma. All participants had at least a 20 pack-year smoking history. For the 22 former smokers in the LIFE group, median smoking cessation duration was 105 months (range, 16-384 months) and the Photographs taken with use of a bronchoscope that employs the laser-induced fluorescence emission (LIFE™) system (Xillix Technologies). A) a LIFE class I finding representative of histologically normal bronchial tissue; B) a LIFE class II finding representative of histologically abnormal bronchial tissue secondary to inflammatory, preneoplastic, traumatic, or vascular processes; and C) a LIFE class III finding representative of bronchial tissue that was considered to be suspicious for moderate or severe dysplasia or carcinoma.
corresponding figure for the former smokers in the control group was 19 months (range, 12-96 months).
LIFE Imaging and the Detection of Squamous Metaplasia and Dysplasia
Since cigarette smoking has been shown to increase levels of squamous metaplasia in the bronchial epithelium (9), we analyzed the data after stratifying them by the smoking status ( Table 2 ). The mean Metaplasia Index and the percentage of participants with a metaplasia index greater than or equal to 15% were significantly higher in current smokers than in former smokers (33.2 versus 4.5, P ‫ס‬ .0001; 74% versus 23%, P ‫ס‬ .02, respectively), regardless of the bronchoscopy equipment used. The mean Metaplasia Index and percentage of participants with Metaplasia Index greater than or equal to 15% were similar in the LIFE and the control groups for both former smokers (4.4 versus 4.7, P ‫ס‬ .706; 23% versus 25%, P ‫ס‬ 1.0, respectively) and current smokers (38.8 
Evaluation of Pathologic and LIFE-Imaging Analyses by Biopsy Sites
From the 39 participants in the LIFE group, 252 biopsy specimens were obtained and 245 of them contained adequate mucosal tissue for histologic evaluation. The results of the evaluation of the 245 biopsy sites by a single pathologist (J. Y. Ro) are shown in Table 3 , A. Among the 245 biopsy samples, mild dysplasia alone was detected in two tissue samples (0.8%), metaplasia and mild dysplasia in six (2.4%), metaplasia alone in 52 (21.2%), and 185 tissue samples (75.5%) were histologically normal. LIFE analysis of the 245 biopsy sites revealed class III findings in 16 (6.5%), class II findings in 89 (36.3%), and class I findings in 140 (57.1%). Of the two sites containing mild dysplasia alone, one was class I and the other one was class II by LIFE analysis. Of the six samples containing both metaplasia and mild dysplasia, four (67%) were found to be class I and two (33%) were class II. An independent analysis of 251 biopsy specimens was carried out by another pathologist (W. A. Franklin) ( Table 3, B) . Of the 251 sites, 234 were deemed adequate for histopathologic examination. Dysplasia was detected in 18 of the 234 biopsy specimens; of these, nine (50%) were class I, eight (44%) were class II, and only one (6%) was class III. The frequency of dysplasia in the two independent evaluations was statistically different (P ‫ס‬ .05 by Fisher's exact test).
When the LIFE imaging was related with pathologic findings by J. Y. Ro ( . A major goal of this study was to determine the utility of the LIFE system in the detection of squamous metaplasia and dysplasia. In this population, these data clearly indicate that abnormalities detected by LIFE bronchoscopy did not associate with the presence or absence of squamous metaplasia and/or mild dysplasia. 
Relationship of LIFE Imaging With Prior Cancer and Smoking Status
To determine whether abnormalities detected by use of LIFE bronchoscopy might reflect lung cancer risk factors other than histologic abnormalities, LIFE findings were related with cancer history (prior smoking-related cancer or not) and smoking status (current or former smoker). Abnormalities (class II or III) found with the LIFE technology were reported in 45 (40%) of 111 biopsy specimens from the participants with a prior history of smoking-related cancer and in 60 (43%) of 141 specimens from those without a prior history of cancer. The corresponding figures for the current and the former smokers were 50 (44%) of 114 and 61 (44%) of 138 biopsy specimens, respectively. In this population, abnormalities found with LIFE bronchoscopy were not associated with the history of a prior smoking-related cancer (P ‫ס‬ .80 by chi-squared test) or smoking status (P ‫ס‬ 1.00 by chi-squared test).
Discussion
In this study, we examined the utility of autofluorescence bronchoscopy with the Xillix LIFE system to detect squamous metaplasia or dysplasia in current and former smokers. We found that, in this population, LIFE imaging did not yield a significantly higher metaplasia index or proportion of participants with elevated metaplasia index or dysplasia than white-light bronchoscopy alone. Furthermore, abnormalities detected by LIFE imaging did not associate with the presence of squamous metaplasia, dysplasia, prior smoking-related cancer history, or smoking status.
Prior studies demonstrated the LIFE system to be effective in the detection of moderate-to-severe dysplasia and carcinoma in situ (7, 8, 10) . However, moderate-to-severe dysplasia and carcinoma in situ were not detected in this study, and the prevalence of dysplasia in these 39 participants was lower than that in the 94 subjects studied by Lam et al. (8, 10) . It is not clear why the prevalence of moderateto-severe dysplasia differs so greatly in the two studies. Lam et al. (8) enrolled subjects with known or suspected lung carcinoma. Although our study did not include any patients with active cancer, 15 participants in the LIFE group had a history of a smoking-related cancer. Besides the difference in the study population, the prevalence of dysplasia may differ in these studies because the criteria by which the pathologists graded dysplasia was different. In fact, the independent review of the representative sections in our study revealed more dysplasia than the initial reports.
Nevertheless, LIFE-imaging abnormalities did not predict the presence of dysplasia in this study. Obviously, interobserver variability might be a contributor. However, the results of independent analyses indicate that the difference in histologic evaluation did not alter the relationship between LIFE abnormalities and bronchial histology. It is also possible that bronchoscopic technique may have been an important variable, but the bronchoscopists in this study underwent training by investigators from Xillix Technologies, and the LIFE equipment was calibrated by service technicians from the Xillix Technologies and met their performance criteria. In addition, the relationship between LIFE imaging and histologic findings of biopsy samples from the first 19 participants did not differ from that of the last 20 (data not shown), suggesting consistency in the performance of the bronchoscopists and pathologists in this study.
Exposure to cigarette smoke is a major lung cancer risk factor and smoking cessation reduces lung cancer risk. However, an increased risk persists in former smokers (9) , suggesting that premalignant changes remain in the bronchial epithelium of former smokers. Screening measures that will identify high-risk individuals among a large population with a history of smoking or a prior smokingrelated cancer are essential to the design of future lung cancer chemoprevention trials. In this study, LIFE-imaging abnormalities did not associate with prior cancer history or smoking status. Overall, our findings do not support the routine use of LIFE bronchoscopy as a lung cancer screening method in the population that was the focus of this study. However, further investigations into other novel bronchoscopic techniques should be performed to design more effective lung cancer chemoprevention strategies. Around 10% of epithelial ovarian cancers are considered to have a hereditary component, with first-and second-degree relatives exhibiting breast, ovarian, or other cancers (1, 2) . In a substantial portion of these familial cases, germline mutations have been detected in the BRCA1 or BRCA2 genes (3) (4) (5) (6) . Genetic testing of asymptomatic family members is currently feasible (7, 8) , but the precise clinical implications of such screening for patient management and prevention schemes are still under investigation (9) .
The majority of these mutations are unique to each high-risk family. In certain populations, a limited repertoire of mutations has been detected in high-risk individuals, presumably reflecting a common ancestral origin. Examples of mutations that account for the majority of BRCA1 or BRCA2 germline mutations in specific populations include the 999del5-BRCA1 mutation in Iceland, the 5382insC- BRCA1 mutation in Russia and in Israel, a n d t h e 1 8 5 d e l A G -B R C A 1 a n d 6174delT-BRCA2 mutations in patients of Jewish descent (10) (11) (12) (13) (14) . Preliminary screening of unselected Jewish patients with invasive ovarian tumors revealed that a high proportion (20%-60%) of them carried one of the latter two mutations, regardless of their family history of breast or ovarian cancer (11, (15) (16) (17) . The high frequency of 185delAG-BRCA1 and 6174delT-BRCA2 mutations in Jewish patients with ovarian cancer (around 30%, as opposed to 2% in the general Ashkenazi Jewish population-i.e., Jews of Eastern/Northern European descent) enables one to investigate whether borderline tumors are associated with either of these germline mutations. Borderline tumors of the ovary, also referred to as epithelial ovarian tumors of low malignant potential, represent a distinct clinical entity of ovarian tumors. They account for 10%-15% of ovarian cancers (18) , occur at a younger age, and have a significantly better prognosis than their invasive counterparts (19) (20) (21) . They have been considered by some authors (22) to be precursors of invasive ovarian cancers. These tumors share some of the histologic features of malignant epithelial ovarian tumors but are characterized by the absence of identifiable, destructive stromal invasion (23) (24) (25) (26) . Borderline ovarian tumors appear to be underrepresented among cases of hereditary ovarian cancer (27, 28) . Little is known about the molecular mechanisms involved in the tumorigenesis of ovarian tumors (22) .
The aim of this study was to try to gain additional insight into these questions by comparing the rates in a single academic medical center of BRCA1 and BRCA2 mutations in unselected Jewish patients with borderline tumors with the rates observed in unselected Jewish patients with invasive epithelial ovarian cancer.
Patients and Methods
Anti-coagulated blood (10 mL) was obtained from 84 consecutive patients with ovarian cancers; these patients were seen during an 8-month period from January to August 1997 at the outpatient clinic of the Division of Gynecologic Oncology of the Sheba Medical Center, Tel Hashomer, Israel. Patients with borderline tumors consisted of 44 patients who were the subject of a study on borderline tumors performed in the Division of Gynecologic Oncology of the Sheba Medical Center (21); these patients presented to our follow-up clinic in a consecutive manner, without preselection. The 40 patients with invasive ovarian cancer were newly diagnosed in the Division of Gynecologic Oncology of the Sheba Medical Center since 1996; they entered a prospective observational study on ovarian cancer in Israel. In addition, DNA was obtained from paraffinembedded histologic specimens from two patients with borderline and 19 patients with invasive tumors of the ovary; these patients had been diagnosed and treated previously at the same institution and were entered in the above-mentioned prospective study during the study period. Paraffin blocks were used only when blood samples were unavailable. Finally, we analyzed the BRCA1 and BRCA2 mutation status of several individuals from a single, large family with familial breast/ovarian cancer, including one patient who presented with a borderline tumor during the same period.
All patients were informed about the aims, limits, and implications of genetic testing. All were offered genetic testing regardless of family history. All participants filled out a detailed questionnaire and signed a standardized, informed consent form approved by the Institutional Review Board. In view of the recent immigration and the impact of the Holocaust, only partial family histories were available in most cases, and positive family history was scored as the presence of at least one first-degree relative with breast or ovarian cancer. Pathologic results were independently reviewed by two pathologists, who confirmed the presence of borderline ovarian tumors in 46 patients and of epithelial invasive ovarian cancer in 59 patients. Tumors were staged according to the criteria of the International Federation of Gynecology and Obstetrics (29) .
DNA was extracted from peripheral blood leukocytes and from paraffin-embedded histologic specimens by use of standard techniques, as previously described (30) . Exon 2 of the BRCA1 gene (for the 185delAG-BRCA1 mutation) and exon 11 of the BRCA2 gene (for the 6174delT-BRCA2 mutation) were amplified by the polymerase chain reaction (PCR) by use of previously described primer sequences and protocols (4, 31) . Following successful PCR, heteroduplex formation was accomplished by denaturing 20 L of each PCR for 2 minutes at 94°C in the presence of a denaturing solution, followed by slow cooling to room temperature as previously described (31) . PCR products (200 base-pair fragments) were loaded onto a gelling medium for mutation detection by heteroduplex formation (MDE™ gels; FMC Bioproducts, Rockland, ME) and subjected to electrophoresis for 5 hours at 50 V at room temperature in 0.6× TBE buffer (i.e., 89 mM Tris borate, 89 mM boric acid, and 2 mM EDTA [pH 8]). Following electrophoresis, the gels were stained with 5% ethidium bromide. DNA sequencing was performed by use of a biotinylated primer, as previously described (32) , for each PCR fragment that consistently displayed an abnormal migration pattern on the heteroduplex formation assay. Recently, the 5382insC-BRCA1 mutation located in the 3Ј end of the BRCA1 gene was detected in 2.2% of Ashkenazi patients with breast cancer but not in Ashkenazi patients with ovarian cancer (17) . To exclude the association of this mutation with borderline tumors, we have looked for the existence of the 5382insC-BRCA1 mutation by a modified restriction enzyme analysis, described by Abeliovich et al. (17) . This technique is based on the introduction into the DNA sequence by the mutation of a novel restriction site, allowing for rapid distinction between the normal and abnormal alleles.
Statistical Analysis
The statistical analysis was performed with the use of the SAS software version 6.10 (SAS Institute Inc., Cary, NC). The two-tailed t test was used to compare means between two independent groups. The 2 test with continuity correction was used to test independence in contingency tables. If the minimum expected frequency in two-by-two tables was less than 5, the two-tailed Fisher exact test was adopted. To analyze the influence of a second covariant on the relationship between the main covariant and the outcome variable, we performed binary logistic regression analysis.
Results
The clinical and pathologic characteristics of the 46 patients with borderline and 59 patients with invasive ovarian tumors are shown in Table 1 .
One (2.2%) of 46 patients with borderline tumors carried a 185delAG-BRCA1 mutation, compared with 17 carriers of the 185delAG-BRCA1 and two carriers of the 6174delT-BRCA2 mutations among the 59 patients (32.2%) with invasive cancer (Table 1) ( 2 test with continuity correction, P ‫ס‬ .00028). Thirty-five patients with borderline tumors and 13 patients with invasive ovarian tumors were analyzed for the presence of the 5382insC-BRCA1 mutation. None of these patients carried this mutation. To evaluate the influence of ethnic origin on our results, we divided the population into two groups, patients of Ashkenazi descent and patients of non-Ashkenazi descent. Our analysis indicated that ethnicity was not significantly different between patients with invasive and borderline tumors ( 2 test with continuity correction, P ‫ס‬ .6), whereas the mutation rate remained significantly different between the two tumor categories, after adjustment for ethnicity (logistic regression, P ‫ס‬ .004). This difference remained highly statistically significant for the subset of patients of Ashkenazi descent alone (P ‫ס‬ .0015). Although the frequency of the monitored mutation in non-Ashkenazi patients with ovarian cancer was 17% (two of 12) compared with none in the non-Ashkenazi patients with borderline tumors (zero of 14) , the presence of only two mutations in non-Ashkenazi patients was not enough to allow appropriate statistical analysis.
The distribution of histologic subtypes, serous and other versus mucinous, differed between borderline and invasive ovarian tumors ( 2 test with continuity correction, P ‫ס‬ .025), but the mutation rate remained significantly different between borderline and invasive tumors, after adjustment for histologic subtypes (logistic regression, P ‫ס‬ .007).
Analysis of the DNA extracted from the paraffin blocks indicated that neither of the two patients with borderline tumors was found to carry a Jewish founder mutation, compared with two of the 19 patients with invasive ovarian tumors. Reanalysis of the data, after elimination of the 21 cases in which DNA was obtained from paraffin blocks, still revealed a highly statistically significant difference in the frequency of founder mutations in borderline compared with invasive ovarian carcinomas (P ‫ס‬ .0001).
The mean age of the patients at diagnosis (± standard deviation) of borderline tumors was 40 years ± 15 years. For patients with invasive ovarian tumors who were 185delAG-BRCA1 mutation carriers, the mean age was 52 years ± 7.7 years, significantly different from the mean age of 60 years ± 12.3 years for patients with invasive ovarian cancer without mutation (t test for equality of means, P ‫ס‬ .028). The one patient with borderline ovarian tumor who carried the 185delAG-BRCA1 mutation was a 21-year-old Ashkenazi patient with stage IIIc disease, without a family history of breast, ovarian, or other cancer. Three patients with borderline tumors and without detectable mutations were diagnosed prior to age 20 years. The distribution of tumor stage in patients with invasive tumors was similar, irrespective of the presence of a germline mutation (two-tailed Fisher exact test, P ‫ס‬ .74).
One patient with a borderline tumor but without a detectable BRCA mutation had one first-degree relative (mother) who died of breast cancer at the age of 38 years. Another patient with a borderline tumor, but without a detectable BRCA mutation, had a strong family history of breast and ovarian cancers. This proband and her family are presented in Fig. 1 . She is a 31-year-old, single, nulligravida nonAshkenazi patient who was referred to the Oncogenetics Unit at the Sheba Medical Center for genetic counseling and evaluation. She had been diagnosed with stage IIIc borderline ovarian tumor 4 months earlier. Exploratory laparotomy revealed bilateral 15-cm and 8-cm semisolid ovarian masses, 5 L of ascites, and diffuse pelvic and upper abdominal masses. The ovarian tumors were of low malignant potential, and the abdominal implants were noninvasive. Her family history was notable for the presence of four ovarian cancers and one breast cancer over five generations and 123 family members (Fig. 1) . The patient's mother (III-7) had died of a stage IIIc grade 2 ovarian cystadenocarcinoma at the age of 58 years. Three maternal cousins (III-3, III-4, and III-6) had been diagnosed within a period of 12 months of each other with stage IIIc papillary cystadenocarcinomas of the ovary and had died of their disease at the ages of 50, 50, and 61 years, respectively. One of these maternal cousins had a daughter (IV-3) who was diagnosed at the age of 38 years with breast cancer. Thirteen asymptomatic family members were tested for the predominant BRCA1 and BRCA2 mutations in the Jewish population. Five of them tested positive for the 185delAG-BRCA1 mutation, including the asymptomatic sister (IV-6) of the proband. Two affected family members, one with ovarian cancer (III-4) and one with breast cancer (IV-3), were carriers of the 185delAG-BRCA1 mutation. In contrast, the proband, who had a borderline ovarian tumor, did not carry the 185delAG-BRCA1 mutation.
Discussion
This study shows that the 185delAG-BRCA1 or 6174delT-BRCA2 mutations were present in one (2.2%) of 46 cases of borderline ovarian tumors in the tested population of patients of Jewish descent. This finding contrasts significantly with the high rate of mutations in unselected Jewish patients with invasive ovarian tumors in our study (19 cases of 59) (P ‫ס‬ .00028), consistent with findings from other centers (11, (15) (16) (17) . Original reports described the increased incidence of the 185delAG-BRCA1 mutation only in Jews of Ashkenazi descent (8, (12) (13) (14) 17) , although we recently found non-Ashkenazi individuals attending the Oncogenetics Unit at the Sheba Medical Center who were at high risk for breast and ovarian cancers to carry the 185delAG-BRCA1 mutation (33) . Further investigations revealed that 185delAG-BRCA1 mutations in non-Ashkenazi subpopulations occurred at a rate of 0.5%-1% (33) . To investigate whether differences in ethnic origin could have influenced our results, we compared the frequency of mutations in borderline versus invasive tumors in the subpopulation of Ashkenazi patients and found the difference in mutation rate to remain significant. We also performed logistic regression analysis; this analysis indicated that, after adjustment for ethnicity, the difference in mutation rate between borderline and invasive tumors remained significant (P ‫ס‬ .004). Recent data (17) suggested the existence of another Jewish founder mutation located in the 3Ј end of the BRCA1 gene. This mutation, 5382insC-BRCA1, was detected in 2.2% of Ashkenazi patients with breast cancer but not in Ashkenazi patients with ovarian cancer (17) . To evaluate whether this particular mutation could be associated with borderline tumors rather than with invasive ovarian cancer, we analyzed the first 48 samples obtained for the presence of this mutation.
Thirty-five samples were obtained from patients with borderline tumors, and 13 samples were obtained from patients with invasive ovarian cancer. None of the patients carried this mutation.
Mucinous carcinomas are underrepresented in patients with germline BRCA1 mutations (34) . Our population of borderline tumors included a significant number of mucinous tumors (22%), which could have biased our conclusions. Re-analysis of the data after adjustment for histology verified that the difference in mutation rate between borderline and invasive tumors remained significant (P ‫ס‬ .007) Furthermore, one patient with advanced stage borderline ovarian tumor, who is a part of a family with a prominent history of ovarian and breast cancers cosegregating with a 185delAG-BRCA1 mutation, was not a carrier of this specific mutation. These data suggest that the founder Jewish BRCA1 mutation is not associated with an increased risk of borderline ovarian tumors, in contrast to the risk of invasive tumors.
It is widely accepted that an early age of onset of cancer of the breast or ovary is suggestive of an inherited predisposition (35) . In this regard, the patient with a stage IIIc borderline ovarian tumor who was a mutation carrier was 21 years old at diagnosis, 19 years younger than the mean age of diagnosis of borderline tumors in this population (40 years old ± 15 years old). However, five additional patients with borderline tumors, but who were not mutation carriers, were diagnosed before the age of 25 years; three of them were diagnosed before age 20 years. Thus, a young age of patients at diagnosis of borderline ovarian tumors does not necessarily imply the presence of a germline mutation in BRCA1. Conversely, having a family history of breast and/or ovarian cancer does not necessarily indicate an inherited predisposition for borderline tumors, as had already become evident from familial cancer registries (27, 28) .
The occurrence of a somatic mutation in tumor tissue, identical to one of the Jewish founder mutations, is highly unlikely, but technical difficulties, loss of heterozygosity, or other somatic mutations could affect the ability to identify the mutations of interest from tumor material. So that we could minimize this risk, the DNA extracted from the histologic samples was not selected for tumor and reflects a mixture of normal tissue and tumor DNA. In addition, normal DNA was added to the PCR in order to detect mutations by heteroduplex formation that would otherwise be missed because of the possible deletion of the normal allele in the tumor tissue.
The approximately 30% rate of founder mutations in unselected patients with ovarian cancer in this population is consistent with the rate in previous reports (8, (12) (13) (14) 17) . The absence of a positive family history in 13 patients with detect- Fig. 1 . Pedigree of a family showing ovarian carcinoma in four cases (III-3, III-4, III-6, and III-7) and breast carcinoma in one case (IV-3). The 185delAG-BRCA1 germline mutation has been identified in several members, as indicated by the symbol T+. Note that the proband indicated by an arrow (IV-7) , who presented with a borderline tumor, did not carry the 185delAG-BRCA1 mutation, as indicated by the symbol t−.
able germline mutations for 185delAG-BRCA1 (11 patients) or 6174delT-BRCA2 (two patients) probably results from truncated families as a result of the Holocaust or from paternally transmitted mutations, combined with a lack of precise family information on previous generations among many Israeli immigrants.
There is an ongoing debate on whether or not borderline tumors of the ovary represent precursor lesions to invasive epithelial ovarian cancers (22) . Similarities between borderline and invasive tumors have been described (36) (37) (38) . However, most molecular data seem to indicate that the precursor lesions of both tumors are different (39, 40) , and the question remains unresolved. The rate of the 185delAG-BRCA1 and 6174delT-BRCA2 germline mutations was significantly different between unselected Jewish patients with borderline and invasive carcinomas. The analysis of the mutations in the BRCA genes, presented in this study, seems to indicate that the genetic predisposition for borderline and invasive ovarian carcinomas differs. However, one would need to fully sequence the BRCA genes in patients with borderline tumors to search for the existence of a specific BRCA mutation in patients with borderline tumors. The possibility that a single germline mutation may ultimately be found that is common to both invasive and borderline tumors seems highly unlikely, but it is not specifically negated by this study.
Our data do not support the notion that borderline tumors represent precursor lesions to invasive carcinomas of the ovary in patients with a germline BRCA mutation. These patients represent close to one quarter of the ovarian cancer patients in Israel. In addition, if there were a link between borderline tumors and invasive ovarian cancers in familial ovarian cancer, one would have expected to find an increased number of borderline tumors in large registries like the Gilda Radner Familial Ovarian Cancer Registry (28) . Also, a recent cohort study (41) found no association between borderline ovarian tumors and a family history of ovarian cancer.
In summary, the rate of the Jewish founder germline mutations in BRCA1 and BRCA2 genes was significantly lower in borderline tumors of the ovary than in their invasive counterparts. Although we realize that our sample size is relatively small and that confirmation of our results by a larger study is necessary, we conclude that, on the basis of the current findings, Jewish patients with borderline tumors of the ovary (at any age and regardless of family history) would not benefit from genetic testing for the founder Jewish mutations. Further investigations will need to be conducted to search for the existence of specific BRCA mutations that might be particularly associated with borderline ovarian tumors. Bone metastases are a major clinical problem that produces significant morbidity. In metastatic prostate cancer, the skeleton is frequently invaded by prostate tumor cells, which are second only to breast cancer in their osteotropism. It is now generally acknowledged that, besides the anatomical or mechanical theories that implicate the rich vascular anastomoses linking the venous vertebral system and the peri-prostatic venous plexus in this tropism (1), several specific biochemical factors involving both the metastatic cell and the host tissue are implicated in the regulation of bone metastasis formation (2) (3) (4) . Among those factors, the preferential adhesion of prostate carcinoma cells to bone marrow has been proposed as playing a significant role (5) .
References
Bone sialoprotein (BSP) is one of the prominent glycoproteins found in the mineral compartment of bone, constituting 10%-15% of the noncollagenous bone matrix proteins (6) . BSP may play important roles in the regulation of mineralization during bone resorption and formation (7, 8) and may mediate some interactions between bone cells and the mineralized matrix (9, 10) . Until recently, BSP expression was thought to be restricted to mineralizing connective tissue, with the exception of decidual cells and trophoblasts of the developing placenta (11) (12) (13) . Our finding that BSP is ectopically expressed at both the protein and messenger RNA (mRNA) levels in a variety of osteotropic human cancers, such as breast and lung cancers, as well as multiple myeloma, has shed light on potential, important biologic functions for this protein (6, 14, 15) . BSP expression in breast cancer was associated with poor prognosis and, interestingly, with an increased risk that the patient would develop bone metastasis (16, 17) . Prostate cancer, like breast cancer, belongs to the restricted group of highly osteotropic cancers.
Altogether, these observations prompted us to examine the expression of BSP in prostate cancer. In this study, we have evaluated the expression of BSP in a large series of human prostate adenocarcinomas by immunoperoxidase and in situ hybridization techniques. In addition, we have examined the potential prognostic value of the level of BSP expression.
Materials and Methods
Patients and Tissue Specimens
Archival paraffin-embedded tissue samples from human prostate cancers were obtained from the Department of Pathology at the Centre Hospitalier Universitaire de Liège, Belgium. These samples were surgically obtained from 180 patients who had undergone a radical retropubic prostatectomy for localized prostate cancer during the period from 1987 through 1995. No patient who had received prior hormonal therapy, chemotherapy, or radiation therapy was included in the investigation. The ages of the patients and the pathologic stage of their disease are shown in Table 1 . All patients had a clinically confined tumor, classified as stage A (n ‫ס‬ 44) or B (n ‫ס‬ 136) according to the TNM system (18) . Absence of regional or distant extension of the tumor was assessed before surgery by chest x ray, pelvic computed tomography scan, and bone scanning. After histopathologic examination, 99 patients were classified as having tumors of pathologic stage pT2. In 56 patients, extracapsular extension of the tumor (stage pT3A-B) was observed. The remaining 25 patients were categorized as having prostate tumors of stage pT3C because their tumors showed evidence of invading the seminal vesicle. All specimens were evaluated according to the Gleason scoring system (19) ( Table 1) . Results from postoperative monitoring of total serum prostate-specific antigen (PSA) levels were available for 164 of these patients who had been followed for a mean time of 24 months (95% confidence interval [CI] ‫ס‬ 20.8-27.0). For the 16 patients who were lost to followup, there were no significant differences in clinical or pathologic stage, histologic score, and age that biased the study cohort (Wilcoxon rank-sum test). The patients were monitored every 3-4 months for the 1st year after surgery, at least semiannually for the next 2 years, and annually thereafter, by use of PSA measurements and digital rectal examinations. In our series, no patient with undetectable PSA levels had a documented tumor recurrence. Sixteen patients with pT3 tumors (11 with pT3A-B tumors and five with pT3C tumors) underwent immediate adjuvant external radiotherapy (started within 3 months after surgery). In all other patients who received adjuvant therapy (androgen deprivation, chemotherapy, or radiotherapy), this adjuvant treatment was introduced only after a significant rise in serum PSA level was achieved (>1 ng/mL).
Immunohistochemistry
Antibodies and immunodetection of BSP. One tissue block per patient that contained the most representative tumor-bearing areas was selected after we considered the capsular status (pathologic stage) and the Gleason score stated in the pathology report. For example, when a prostate tumor was reported with a Gleason score 7 (grade 4 + grade 3) and a pathologic stage T3, the most representative block was selected according to these tumor characteristics and thus harbored both grades 3 and 4 as well as foci of extracapsular extension. Using two rabbit polyclonal antibodies (LF83 and LF100), we examined the expression of BSP by the immunoperoxidase technique. These antibodies were raised against synthetic peptides of human BSP (LF83, residues 277-294; LF100, residues 129-140) (20) . Both antisera have been checked previously for reactivity by western blotting and shown to react only with BSP (20) . Immunoperoxidase staining was performed by use of the ABC Vectastain Elite kit (Vector Laboratories, Inc., Burlingame, CA) according to the supplier's directions. Briefly, tissue sections were deparaffinized in xylene and rehydrated. After the endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide in methanol for 30 minutes, the slides were incubated with normal goat serum (1 : 20) to block the nonspecific serum-binding sites. Anti-BSP LF83 at a dilution of 1 : 1000 or anti-BSP LF100 at a dilution of 1 : 1500 was applied and incubated overnight at 4°C, followed by incubation with a biotinylated goat anti-rabbit antibody (1 : 200) (30 minutes) and the avidin-biotinperoxidase complex (30 minutes). After each incubation, slides were washed three times with phosphate-buffered saline (PBS) (10 mM sodium phosphate and 0.9% NaCl [pH 7.5]). Peroxidase activity was developed by a solution of 4 mg of 3,3Ј-diaminobenzidine tetrahydrochloride (DAB) (Vel, Leuven, Belgium) dissolved in 10 mL of PBS and 0.03% H 2 O 2 . The DAB solution was filtered, and the sections were incubated for 4 minutes. Finally, Carazzi's hematoxylin was used to counterstain the slides, which were then dehydrated and mounted. Immunoreactivity with the LF83 antibody was evaluated for all 180 tissue sections. Detection of BSP expression with the LF100 antibody was attempted in 30 unselected specimens. Control experiments included omission of the first antibody. For the LF83 antibody, preincubations with a 100 M excess of the corresponding peptide or an unrelated peptide (synthetic peptide of bovine osteonectin LF54, residues 27-56) were performed prior to the antibody's use in the immunoperoxidase assay.
Evaluation of immunohistochemical staining. Two independent observers, who had no knowledge of the patients' outcome, reviewed the immunohistochemically stained sections. When present, normal and hyperplastic glands as well as prostatic intraepithelial neoplasia (PIN) lesions adjacent to the tumor were also evaluated for anti-LF83 and anti-LF100 immunoreactivity. In a primary evaluation, scoring of the staining was arbitrarily done according to the intensity of the staining (0, 1+, 2+, or 3+) and the percentage of positive neoplastic glands within the tumor (0%, <10%, 10%-33%, 34%-66%, or 67%-100%). When the tumors showed some heterogeneity in the intensity of the staining, the scoring of the intensity of the staining was assessed according to the staining of the most positive tumor cells, when their estimated percentage represented at least 30% of the total positive tumor cell area. In a secondary analysis, tumor samples were subclassified with regard to immunostaining intensity and extent according to similar graded scales that ranged from 0 to 3. For staining intensity, the scale used was identical to that described above. For staining extent, 0 represented samples in which BSP expression was undetectable, 1 denoted samples in which up to 33% of the glands exhibited a detectable level of anti-BSP immunoreactivity, 2 signified those with detectable staining in more than one third up to two thirds of the tumor cells, and 3 represented those in which more than two thirds of the tumor cells expressed a detectable level of BSP expression. The results obtained with the two scales were multiplied together, yielding a single scale with steps of 0, 1+, 2+, 3+, 4+, 6+, and 9+, where 0 was considered to be negative staining, 1+ and 2+ were considered to be low staining, 3+ and 4+ were considered to be medium staining, and 6+ and 9+ were considered to be high staining. This multiplied scale subclassification system is similar to that previously described by Sjö-gren et al. (21) .
In Situ Hybridization of BSP mRNAs
Probes. The template used was the full-length human BSP complementary DNA (cDNA) B6-5g (7) cloned in the Stratagene pBluescript SK vector (Stratagene, La Jolla, CA). After linearizing the plasmid with the appropriate restriction enzymes (BamH1 and HindIII for antisense and sense probes, respectively), we obtained a digoxigenin (DIG)-labeled single-stranded antisense RNA probe by use of T7 RNA polymerase (Boehringer Mannheim GmbH, Mannheim, Germany) and a DIG RNAlabeling kit (Boehringer Mannheim GmbH). Similarly, a sense DIG-labeled RNA probe was prepared for negative control experiments by use of T3 RNA polymerase and the same labeling kit.
Harvesting and preparing human prostate cancer tissue. Fresh samples of normal and malignant human prostate tissues were obtained from radical prostatectomy specimens according to the method described by Wheeler and Lebovitz (22) . Briefly, in the operating room, prostate tissue samples were taken from the peripheral zone by use of a 6-or 8-mm-diameter punch biopsy instrument. These samples were immediately placed in TissueTek OCT compound (Miles Inc., West Haven, CT), snap-frozen in liquid nitrogen, and stored at −80°C until sectioning. The tissue sections (8 m thick) used for in situ hybridization were layered onto glass slides coated with 3-aminopropyltriethoxysilane (Sigma-Aldrich S.A., Bornem, Belgium). Serial sections from each specimen were allowed to air-dry prior to fixation for 15 minutes in 4% paraformaldehyde in PBS. After being washed in PBS, the slides were dehydrated through a series of incubations in 30%, 50%, and 70% ethanol, for 5 minutes each. The sections were then stored in 70% ethanol at 4°C until use for in situ hybridization. A serial section from each sample was examined by use of hematoxylin-eosin staining to select normal areas, PIN lesions, and adenocarcinomas. Another serial section was processed for immunohistochemistry by use of the anti-BSP LF83 antibody at a dilution of 1 : 1000.
BSP-mRNA detection by in situ hybridization. The presence of BSP-specific transcripts in primary prostate cancer samples was demonstrated by a nonradioactive in situ hybridization technique (23) (24) (25) . After a hydration step in PBS, tissues were acetylated for 10 minutes in freshly prepared 0.25% acetic anhydride in 0.1 M triethanolamine (pH 8.0) and subsequently rinsed in 0.1 M glycine and 0.1 M Tris (pH 7.0) for 10 minutes. The sections were then dehydrated in increasing ethanol concentrations and air-dried. The hybridization reaction was carried out at 55°C overnight in hybridization buffer (50% deionized formamide, 5× standard saline citrate [SSC], 10% dextran sulfate, 5× Denhardt's solution, 0.5% sodium dodecyl sulfate [SDS] , and 100 g/mL single-stranded DNA). Approximately 30 L of hybridization buffer containing 30 g/mL of DIGlabeled cDNA probes (sense or antisense) was applied to each section. After hybridization, the sections were washed four times (3 minutes each) in 2× SSC and 0.1% SDS and then two times (15 minutes each) in 0.1× SSC and 0.1% SDS at 55°C. The tissues were then treated with 10 mg/mL ribonuclease A (Boehringer Mannheim GmbH) at 37°C for 15 minutes. After being washed with 2× SSC for 2 minutes, the sections were incubated with a sheep alkaline phosphatase-conjugated anti-DIG antibody (Boehringer Mannheim GmbH) for 30 minutes. The alkaline phosphatase reaction was developed by addition of 5-bromo-4-chloro-3-indolyl phosphate and nitroblue tetrazolium for 90 minutes. Finally, sections were counterstained with methyl green and mounted under coverslips for microscopic examination. The intensity of the signal in the carcinoma cells and adjacent normal glands when present was graded on a scale of 0 to 3+ (0, no reactivity; 1+, weak reactivity; 2+, moderate reactivity; 3+, strong reactivity).
Statistical Analysis
Biochemical progression was defined as an increasing total serum PSA level of 0.5 ng/mL or more. To fulfill these criteria, at least two successive determinations of increased total serum PSA levels were required to define biochemical failure. During the period from 1987 through March 1995, PSA testing was performed with the use of the Hybritech Monoclonal Assay (Hybritech Europe, Liège, Belgium), and the level of detectability for this test was greater than or equal to 0.5 ng/mL. In the following months, through March 1997, the PSAUltraSensitive MAGIA Merck test (MerckClevenot, Nogent-sur-Marne, France) was used, and the threshold of detectability was lowered to greater than or equal to 0.1 ng/mL. The actuarial probability of remaining free of biochemical progression was estimated by Kaplan-Meier analysis (26) . The progression-free rates were compared with the use of the logrank test. CIs for the 1-and 3-year progression-free rates were computed on the log-survival scale. Five-year probabilities were not reported because of the small number of men who were followed for this interval of time. The MantelHaenszel 1-degree-of-freedom correlation test was used to assess whether pathologic findings (pathologic stage and Gleason score) were significantly associated with LF83 immunostaining intensity and extent. These variables were analyzed as ordered variables and were coded 1, 2, and 3 for pT2, pT3A-B, and pT3C, respectively; 1, 2, and 3 for Gleason scores 2-4, Gleason scores 5-7, and Gleason scores 8-10, respectively; 0, 1, 2, and 3 and 0, 1, 2, 3, and 4 for LF83 staining intensity and extent, respectively, according to the scale described in the previous section entitled ''Evaluation of Immunohistochemical Staining.'' To account for more than one prognostic variable simultaneously, the clinical and histologic parameters (stage and score) and BSP expression were evaluated by use of a multivariate Cox proportional hazards model (27) (with stepwise procedure) to determine which variables were independently correlated with progression. The data were consistent with the assumptions of Cox proportional hazards analysis. The dichotomization of LF83 immunostaining intensity and that of the multiplied scale were chosen as 0 and 1+ versus 2+ and 3+ and were specified prior to multivariate analysis. All statistical tests were two-tailed, and P<.05 was considered statistically significant. The analyses were performed with statistics software packages (SAS Institute Inc., Cary, NC; and S-Plus, MathSoft Inc., Seattle, WA).
Results
The expression of BSP was evaluated by immunoperoxidase staining in paraffin sections of primary prostate cancer obtained from 180 patients who had undergone a radical prostatectomy for localized prostate cancer. Epithelial cells from normal glands exhibited no or a low, but detectable, level of BSP (Fig. 1, C and D) . We observed that, in some PIN glands, when present, BSP expression was increased compared with normal cells (Fig.  1, F) . Of the 180 prostate cancer lesions studied, 142 (78.9%) expressed detectable levels of BSP (1+, 2+, or 3+) (Fig. 1, C,  D , E, and G). The immunoreactivity was mainly cytoplasmic. In most lesions, BSP expression was heterogeneous within the same tumor (Fig. 1, H) . BSP was also detected with the use of the LF100 polyclonal antibody in 30 unselected prostate cancer samples. Both anti-BSP antibodies (LF83 and LF100) generated the same degree and pattern of specific staining (data not shown). Positive staining was abolished by omission of the primary antibodies and was significantly reduced by preincubation with a 100 M excess of the corresponding synthetic peptide (Fig. 1, A and B). No significant difference in LF83 was observed after preincubation of the antibody with a 100 M excess of an unrelated peptide (data not shown).
The intensity of BSP expression significantly correlated with the extension of the primary tumor (from organ confined [pT2] to extracapsular [pT3A-B] to seminal vesicle-invading tumors [pT3C]) (Mantel-Haenszel test, P ‫ס‬ .04), but it was not significantly associated with tumor differentiation, expressed according to the Gleason score (Mantel-Haenszel test, P ‫ס‬ .10). We found a borderline association between the extension of the tumor and the extent of the LF83 staining (Mantel-Haenszel test, P ‫ס‬ .052). In the multiplied scale system, which takes into account both the heterogeneous pattern and the intensity of BSP expression, a significant association was observed between subclass scores (0 versus 1-2 versus 3-4 versus 6-9) and the pathologic stage of the prostate tumors (MantelHaenszel test, P ‫ס‬ .012).
Monitoring measurements of postoperative total serum PSA levels were available for 164 of the 180 patients. (Fig. 2, A ). An increased extent of LF83 immunostaining was also associated with a significantly higher PSA relapse rate (logrank test, P<.001). The data were analyzed considering the different subclasses obtained from the more complex multiplied scale grading system (intensity × extent of staining). We observed significant differences between PSA progressionfree rates of the different categories from the four-grade scale (0 versus 1-2 versus 3-4 versus 6-9) (logrank test, P ‫ס‬ .003) (Fig. 2, B ). In the group of patients with pathologically confined tumors (pT2), significant differences were found in relapse-free survival rates between patients with tumors expressing low levels of BSP and those with tumors expressing high levels of BSP, with a worse prognosis for patients with tumors highly positive for BSP (logrank test, P ‫ס‬ .014). The 3-year PSA-relapse frequency was 2.3% (95% CI ‫ס‬ 0%-6.6%) in the group of patients with tumors expressing low levels of BSP compared with 14.1% (95% CI ‫ס‬ 0%-26.5%) in the group of patients with tumor expressing high levels of BSP (Fig.  2, C) . It is interesting that none of the patients with pT2 tumors that did not exhibit BSP (staining intensity 0) had a PSA relapse. Estimated 3-year biochemical progression-free rates for well-differentiated (Gleason scores 2-4), moderately differentiated (Gleason scores 5-7), and poorly differentiated (Gleason scores 8-10) cancers were 95% (95% CI ‫ס‬ 85.9%-100%), 74.7% (95% CI ‫ס‬ 64.6%-86.3%), and 38.5% (95% CI ‫ס‬ 21.3%-69.7%), respectively (logrank test, P<.0001). In the large group of 124 patients with moderately differentiated tumors, significant differences were observed in biochemical relapse-free rates between patients with prostate tumors that exhibited a low level of LF83 immunoreactivity (group 1) and those with tumors that were highly positive for BSP (group 2) (logrank test, P ‫ס‬ .011). The 3-year relapse-free survival rate in the first group was 92.8% (95% CI ‫ס‬ 83.6%-100%), as opposed to 64.6% (95% CI ‫ס‬ 51.3%-81.4%) in the second group (Fig. 2, D) .
Sixteen patients with extracapsular disease (pT3A-B-C) had undergone immediate adjuvant radiation therapy following radical prostatectomy. To exclude any bias that might affect the survival results in the group of patients with pT3A-B-C cancers who were irradiated and the group of patients with pT3A-B-C tumors who were not irradiated, we compared the groups with regard to clinical or pathologic stage, histologic score, and age; however, we did not find any significant differences (Wilcoxon rank-sum test). Time to PSA relapse was then evaluated in these two populations of patients with pT3A-B-C cancers (immediate adjuvant Fig. 2 . Biochemical progression-free rates in patients with clinically localized prostate cancer. Biochemical progression was defined as an increasing total serum prostate-specific antigen (PSA) level of 0.5 ng/mL or more. Tick marks on the curves indicate censored patients. Representative 95% confidence intervals (CIs) are shown in panels A, C, and D. Patients at risk for each category of bone sialoprotein (BSP) immunostaining are shown below each panel. All reported P values are two-sided. Panel A: Actuarial probability of freedom from progression according to BSP expression for 180 patients with clinically localized prostate cancer who were treated by radical prostatectomy. We observed a significantly higher 3-year PSA relapse rate in patients with tumors exhibiting a high level of BSP expression (staining intensity 2+ or 3+) (36.7% [95% CI ‫ס‬ 23.4%-47.7%]) than in patients whose tumors expressed no or low detectable levels of BSP (staining intensity 0 or 1+) (12.1% [95% CI ‫ס‬ 2.3%-20.8%]) (logrank test, P ‫ס‬ .0014). Panel B: Actuarial biochemical progression-free disease according to the intensity and the extent of BSP expression. The whole population of 180 patients was categorized according to anti-BSP immunostaining intensity and extent following a multiplied 4-grade scale described in the ''Materials and Methods'' section. For legibility purpose, the additional lines that represent 95% CIs are not shown. Three-year progression-free estimates were 87.9% (95% CI ‫ס‬ 75.6%-100%), 71.9% (95% CI ‫ס‬ 60.2%-86%), 74.3% (95% CI ‫ס‬ 59.1%-93.5%), and 52.3% (95% CI ‫ס‬ 31.3%-87.2%) in patients with no detectable BSP staining (0), low staining (1-2), medium staining (3-4), and high staining (6) (7) (8) (9) , respectively (logrank test, P ‫ס‬ .003). Panel C: Actuarial PSA relapse rates in the 99 patients with pT2 tumors. A higher biochemical progression rate was observed in patients with pT2 tumors that expressed high levels of BSP expression (staining intensity 2+ or 3+) than in those with tumors expressing no or low levels of the protein (staining intensity 0 or 1+) (logrank test, P ‫ס‬ .014). Panel D: High expression of BSP (staining intensity 2+ or 3+) by the tumor cells was associated with a higher risk of biochemical progression in patients with moderately differentiated tumors (Gleason scores 5-7) (logrank test, P ‫ס‬ .011).
radiotherapy versus no immediate adjuvant treatment). Three-year progressionfree rates were 62.3% (95% CI ‫ס‬ 40.1%-96.7%) and 45.4% (95% CI ‫ס‬ 31.2%-66%) for patients with and without adjuvant radiation therapy, respectively (logrank test, P ‫ס‬ .43). Because we observed no difference in intensity of BSP expression between those two groups of patients (Wilcoxon rank-sum test, P ‫ס‬ .26), we could conclude that our estimate of the association between BSP and PSA relapse was not altered by adjuvant radiotherapy.
A Cox proportional hazards model for multivariate analysis was developed to investigate whether prognostic information generated by BSP expression was positively or negatively confounded by other commonly used prognostic markers. To evaluate the additional prognostic information associated with the detection of BSP, we used Cox's proportional hazards model to estimate the 1-year and 3-year progression-free survival rates based on the Gleason score alone and after combining the Gleason score and BSP intensity ( Table 2 ). The results of this analysis were particularly striking in the groups of patients with Gleason score 5-7 and score 8-10 tumors. For example, if the Gleason score was the only covariate entered in the model, the analysis estimated a 38% progression-free survival rate at 3 years for the group of patients with Gleason score 8-10 tumors. When we added BSP intensity to the multivariate analysis, important differences in the 1-year and 3-year progression-free rates were observed. A comparison between the progression-free rates of the entire group of patients with Gleason score 8-10 tumors (67.6% and 38% at 1 and 3 years, respectively) and those of two subgroups of patients with score 8-10 tumors that expressed low (0 or 1+) or high (2+ or 3+) levels of BSP yielded significant differences. In extenso, the estimated risk of relapse for a patient with a Gleason score 8-10 prostate tumor in this series was 62%. If this patient's tumor expressed low levels of BSP, the relapse risk was reduced to 34.6% and was nearly the same as that of a patient with a Gleason score 5-7 tumor that expressed high levels of the protein (32.8%). Conversely, if high levels of BSP were detected in the cells of a score 8-10 tumor, the estimated risk of PSA relapse was increased to 74.9%. These data clearly show that BSP detection can significantly contribute to a more accurate identification of patients with poor prognosis.
In situ hybridization with sense and antisense riboprobes was performed on eight representative prostate cancer specimens in order to demonstrate the presence of BSP mRNA in the prostate carcinoma cells. Sense and antisense BSP riboprobes were prepared and applied to serial prostate cancer sections. The expression of BSP mRNA was high in prostate cancer glands as compared with that in normal glands, which exhibited no or a low level of the transcripts (not shown). BSP mRNA was also detected in some PIN lesions. The level of expression of BSP mRNA was usually consistent with the amount of the protein detected by immunoperoxidase. Control experiments in which the sense riboprobe was used showed no specific reactivity (data not shown).
Discussion
The search for reliable predictors of prostate cancer progression is a major and urgent research challenge for the next few years. A wide discrepancy exists between the steadily increasing number of subclinical malignant lesions diagnosed and the prevalence of those lesions that actually will progress to clinically overt disease (28) (29) (30) (31) (32) (33) . There is, therefore, an essential need for better pretherapeutic assessment of the aggressiveness of these lesions. Prostate cancer progresses along a predictable pathway: invasion of the draining lymph nodes through the lymphatic routes and colonization of the skeleton through hematogeneous dissemination (34) . Bone metastases are a constant feature of advanced prostate cancer and create major morbidity (35) (36) (37) . Until now, little has been known about the mechanisms that lead circulating metastatic prostatic cells to target bone as a preferred site for the successful initiation of a secondary lesion. Potential clues that could help to unveil the mechanisms of bone metastasis formation are provided by the recent observation that several osteotropic cancers, including breast and lung carcinomas as well as myeloma, ectopically express BSP (6, 14, 15, 20) . Our finding that BSP expression in primary breast cancer correlates with both the development of bone metastases and patient survival (16, 17) suggests that this protein could play a role in the determination of the osteotropic phenotype of metastatic cancer cells. It is now generally acknowledged that cross talk between cancer cells and their host tissues is critical for the initiation of a metastasis. We have recently proposed that ectopic BSP expression by circulating malignant cells could favor their interactions with mineralized bone matrix, e.g., mediate the cells' attachment to hydroxyapatite crystals. The demonstration that breast cancer cells that metastasize to bone express the integrin ␣ v ␤ 3 , a cell surface receptor that uses BSP as a ligand, is in agreement with our hypothesis (38-43) . Further support for this concept is provided by the recent report that BSP-derived peptides bearing the RGD (i.e., arginine-glycine-aspartic acid) sequence can inhibit the adhesion of breast cancer cells to bone (44) . If ectopic expression of BSP is associated with the osteotropic phenotype, it would be expected that this bone matrix protein would also be detected in the cancerous cells originating from other osteotropic cancers. Indeed, lung (14) and breast (17) cancers were frequently found to express BSP. In this study, we have demonstrated that BSP expression is also a common phenotypic feature of human prostate cancers, the second most osteotropic cancer known. In situ hybridization experiments demonstrated that BSP mRNA was expressed in prostate carcinoma cells that exhibited high levels of immunoreactivity with the anti-BSP antibodies. The level of BSP expression was significantly associated with the pathologic stage of the tumor. In contrast, only a weak trend of association was observed between BSP expression and another commonly accepted prognostic marker, the histologic score of the tumor (45) (46) (47) (48) (49) (50) . Total serum PSA is unanimously recognized as the most important and clinically significant tumor marker available to date. Since 1987, PSA testing has been commonly used to monitor the patient's response to prostate cancer therapy. An increasing level of PSA after curative treatment is, in most cases, the first indicator of recurrence. In this study, we demonstrate that a high level of BSP expression is independently associated with a higher risk of PSA relapse in patients who have undergone a radical prostatectomy for clinically confined prostate cancers. Patients with prostate tumors of intermediate Gleason scores 5-7 (moderately differentiated) represent the largest group with prostate cancer. These patients represent the ''gray zone'' cohort because disease recurrence may be highly variable from one patient to another. One interesting finding in this study is the observation that the level of BSP expression provides valuable additional prognostic information in this group of patients. Indeed, the detection of high levels of the protein significantly identifies a group of patients with a higher risk of biochemical progression. Because of the long follow-up that is necessary, it is not clear yet whether these results are predictive of the clinical outcome in terms of survival and, more particularly, of the development of bone metastases. PSA relapse in the group of patients with pathologically confined tumors (pT2) is usually low and varies from 6% to 18% at 5 years, depending on the cut point used to define biochemical progression (49, 51, 52) . Our data reveal that up to 17% of patients with pT2 prostate tumors demonstrate PSA elevation at 5 years (results not shown). We observed that patients with pT2 tumors that express high levels of BSP show a significantly higher 3-year PSA recurrence rate than patients with pT2 tumors that express no or low levels of the protein. It is interesting that none of the patients with pT2, BSP-negative prostate cancers had PSA relapse on follow-up. We might then hypothesize that, in the group of patients with pT2 cancers who were treated and believed to be cured by radical prostatectomy, ectopic BSP expression is a required event for disease progression. If studies performed on larger cohorts of patients confirm these data, then BSP detection could be used to identify the risk that a patient's tumor will progress.
Invasion of the seminal vesicles (stage pT3C) is associated with a high rate of disease progression. For this group of patients, the prognosis is nearly as poor as that for patients with lymph node metastases (45, 49, (53) (54) (55) . In our series, we observed that, within 3 and 5 years of follow-up, 54% and 70% of patients, respectively, with pT3C tumors had PSA recurrence (results not shown). In the group of patients with pT3C tumors, we observed a high rate of BSP expression by the tumor cells, with 96% of the pT3C prostate specimens exhibiting detectable levels of the protein (results not shown).
Finally, we showed that BSP detection, when combined with the Gleason score, may provide clinicians with valuable additional prognostic information to evaluate with increased accuracy the outcome for a patient who has undergone a radical prostatectomy for clinically confined prostate cancer.
In conclusion, to our knowledge, we demonstrate for the first time in this study that BSP is ectopically expressed in most human prostate cancers and that a high level of BSP expression is associated with a higher risk of biochemical progression after radical prostatectomy for localized prostate cancer. The best pretherapeutic assessment of prostate tumor aggressiveness will probably result from the detection of biologic markers associated with the invasive and metastatic phenotype of the tumor cells. This challenge will be met when use of such markers allows an accurate prediction of the risk of tumor progression for an individual patient. It is likely that a combination of several markers will be required to provide the clinicians with sufficient confidence to decide which patient would benefit from watchful waiting, from immediate radical prostatectomy, or from other treatments.
We have recently demonstrated that the 67-kd laminin receptor (67LR), a protein associated with the invasive phenotype of malignant cells, was an independent prognostic marker of PSA relapse in patients who have been treated by radical prostatectomy for localized prostate cancer (56) . In the near future, we shall determine whether the combination of the two biologic markers (67LR and BSP) offers additional value in the prognostic evaluation of prostate cancer lesions. Furthermore, with the demonstration that expression of BSP is a common feature in prostate cancer, a highly osteotropic cancer, we have an accumulation of evidence that incriminates this bone matrix protein in the process of bone metastasis formation. Our new challenge now is to determine how and when BSP expression is turned on in the oncogenic process and to investigate the specific potential molecular roles that this bone matrix protein may play during bone colonization. It is tempting to speculate that the identification of these mechanisms could lead to a putative treatment to prevent bone metastases.
